Arkolith/Insider Trading/KNTE/Form 4

Gordon Carl L

Director, 10% OwnerKinnate Biopharma Inc. (KNTE) · full profile →Form 4 · filed May 8, 2023
Net Buying
Open-Market Buys
$4.1M
Open-Market Sells
$0
Net Open-Market Flow
$4.1M
Transactions
5
5 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 5, 2023Buy(P)491K$2.82$1.4M1.4M
May 5, 2023Buy(P)491K$2.82$1.4M1.4M
May 4, 2023Buy(P)313K$2.75$861K4.7M
May 4, 2023Buy(P)83K$2.75$230K878K
May 4, 2023Buy(P)83K$2.75$230K878K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000947871-23-000540) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML